Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231

			•	
U.S. APPLICATION NO.	FIRST NAMED APPLICANT		ATTY, DOCKET NO.	
09/786235	GAJEWEZYK	D	1038-1129 MI	
		INTERNATIO	INTERNATIONAL APPLICATION NO.	
SIM & MCBURNEY 330 UNIVERSITY AVENUE		PCT/	PCT/CA99/00807	
6TH FLOOR TORONTO, ONC 517		I.A. FILING DATE	PRIORITY DATE	
· c.	•	03 SEP 99	04 SEP 98	

DATE MAILED: 02 APR 2001

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

reason(s).	
The application fails to comply with the requirem	
This application does not contain, a "Sequence L	
disclosure on paper copy or compact disc, as rec	puired by 37 CFR 1.821(c).
A copy of the "Sequence Listing" in computer re	adable format has not been submitted as
required by 37 CFR 1.821(e).	
A copy of the "Sequence Listing" in computer re	
content of the computer readable form, however, 37 CFR 1.822 and/or 1.832, as indicated on the a	does not comply with the requirements of attached marked-up copy of the "Raw
Sequence Listing."	
The computer readable form that has been filed v	
damaged and/or unreadable as indicated on the a substitute computer readable form must be submit The paper copy or compact disc of the "Sequence	itted as required by 37 CFR 1.825(d).
computer readable form of the "Sequence Listing	
Other:	, as 104=1100 by 0, 01 K 1.021(0).
APPLICANT MUST PROVIDE: An initial or substitute computer readable form (0 An initial or substitute paper copy or compact disamendment directing its entry into the specification A statement that the contents of the paper or compare the same and, where applicable, include no not 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d)	se of the "Sequence Listing," as well as an on. pact disc and the computer readable form ew matter, as required by 37 CFR
FOR QUESTIONS REGARDING COMPLIANCE WITH T CALL:	HESE REQUIREMENTS, PLEASE
(703) 308-4216, for Rules interpretation,	
(703) 308-4212, for CRF submission help,	
(703) 287-0200, for PatentIn software help.	
	Pat Booker, Paralegal
Tele	ephone: (703)305-3738

FORM PCT/DO/EO/920 (March 2001)